抗鲍曼不动杆菌药物研究进展  

Research Advances in Antibacterial Agents Resistance to Acinetobacter baumannii

作　　者：刘坤锋[1] 吴洁[1] 顾觉奋[1] 

机构地区：[1]中国药科大学生命科学与技术学院,南京210009

出　　处：《国外医药（抗生素分册）》2013年第5期193-196,共4页World Notes on Antibiotics

摘　　要：鲍曼不动杆菌已经成为院内感染的主要病原体,并且随着多重耐药鲍曼不动杆菌(MDRAB)的增加,对它的治疗已经受到重视。本文着重介绍了针对多重耐药鲍曼不动杆菌的抗生素,药物联用仍是有效方法。新型肽类抗生素如人β-防卫素2、(LLKK)2C和[E4K]alyteserin-1c等具有抗菌活性高、副作用小等优点,具有很好的应用前景。Acinetobacter baumannii had emerged as a major pathogen causing hospital infections. With the increase of multidrug-resistant Acinetobacter baumannii （MDRAB）, there is a clear need to seek therapeutic approaches. Antibacterial agents for MDRAB infections were mainly introduced in this article. Combination of antibiotics was still the effective method. New peptide antibiotics such as Human β-defensin 2, （LLKK）2C and [E4K] alyteserin-1c could hopefully be ideal antibacterial agents with advantages of potent antibacterial activity and little side effects.

关 键 词：MDRAB 耐药 联合用药 抗菌肽 

分 类 号：R378[医药卫生—病原生物学]